🇺🇸 FDA
Patent

US 11311517

Combination of small molecule CD-47 inhibitors with other anti-cancer agents

granted A61KA61K31/4245A61K45/06

Quick answer

US patent 11311517 (Combination of small molecule CD-47 inhibitors with other anti-cancer agents) held by Aurigene Discovery Technologies Limited expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aurigene Discovery Technologies Limited
Grant date
Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/4245, A61K45/06, A61P, A61P35/00